Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates

Organon & Co Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates (Businesswire) 2022-06-13 14:30 Organon announces first biosimilars business deal with a global license agreement with Henlius.

Read the source article at Välkommen till Avanza
2022-06-13 16:30:00